TTrialPathMatch Me to Trials
← Back to trials
RecruitingCarotid Artery Diseases

A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach

Eligible age

18–79 yrs

Accepts

All genders

Locations

7 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The objective of this study is to evaluate acute device and technical success of the CGuard Prime™ Carotid Stent System (80cm) when used in conjunction with the Enroute NPS during Transcarotid Artery Revascularization procedures in the treatment of carotid artery stenosis in spatients at high risk for adverse events from carotid endarterectomy.

Sponsor: InspireMD

You may qualify if…

  • Patient is ≥ 18 years and \< 80 years of age.
  • Patient is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements.
  • Patient is diagnosed with carotid artery disease treatable with a Carotid Artery Stent via a Transcarotid Artery Revascularization approach and is either symptomatic or asymptomatic, defined as:
  • Symptomatic carotid stenosis ≥ 50%. Symptomatic is defined as amaurosis fugax, transient ischemia attack (TIA) or stroke within the last 6 months ipsilateral to the side of the stenosis Or
  • Asymptomatic carotid stenosis ≥ 80%
  • High Risk condition for CEA: at least one, as shown below:
  • Comorbid conditions:
  • Age ≥ 70 (maximum 80 years)

You may not qualify if…

  • Patient had or will have an interventional procedure or surgery of the carotid, coronary or peripheral arteries within 30 days before or after the index carotid procedure.
  • Patient had or will have open heart surgery or valvular intervention (percutaneous or surgical), or any major operation, within 30 days before or after the index carotid procedure.
  • Vascular anatomy that would preclude safe sheath insertion or deliverability of stent
  • Patient had a previously placed stent in the ipsilateral ICA or CCA.
  • Total occlusion or presence of a "string sign" of the ipsilateral ICA or CCA.
  • Presence of a filling defect of the target lesion.
  • Tandem lesions, which cannot be covered by a single CGuard Prime™ stent.
  • Patient has a stenosis of the innominate artery or proximal CCA requiring revascularization

Where it's recruiting

California

Sacramento

Indiana

Indianapolis

Minnesota

Minneapolis

Missouri

St Louis

Montana

Great Falls

New York

New York · Rochester

Ohio

Cincinnati

Source: ClinicalTrials.gov · NCT06653387 · last updated 2025-05-31

A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Suc · TrialPath